ZSCAN1 and rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome: Our analyses indicate anti-ZSCAN1 autoantibodies as a marker for early diagnosis that may also be useful in evaluating disease severity and the need for immunosuppressive treatment in patients with ROHHAD syndrome not associated with a tumor.